Skip to Content
Merck
  • Defining the origin, evolution, and immune composition of SDH-deficient renal cell carcinoma.

Defining the origin, evolution, and immune composition of SDH-deficient renal cell carcinoma.

iScience (2022-11-09)
Joana B Neves, Kirsty Roberts, Janani Sivakumaran Nguyen, Soha El Sheikh, My-Anh Tran-Dang, Catherine Horsfield, Faiz Mumtaz, Peter Campbell, Hans Stauss, Maxine G B Tran, Thomas Mitchell
ABSTRACT

Succinate dehydrogenase (SDH)-deficient renal cell carcinoma represents a rare subtype of hereditary kidney cancer. Clinical diagnosis can be challenging and there is little evidence to guide systemic therapeutic options. We performed genomic profiling of a cohort of tumors through the analysis of whole genomes, transcriptomes, as well as flow cytometry and immunohistochemistry in order to gain a deeper understanding of their molecular biology. We find neutral evolution after early tumor activation with a lack of secondary driver events. We show that these tumors have epithelial derivation, possibly from the macula densa, a specialized paracrine cell of the renal juxtaglomerular apparatus. They subsequently develop into immune excluded tumors. We provide transcriptomic and protein expression evidence of a highly specific tumor marker, PAPPA2. These translational findings have implications for the diagnosis and treatment for this rare tumor subtype.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Collagenase Type IV, Cls IV
Roche
DNase I recombinant, RNase-free, from bovine pancreas, expressed in Pichia pastoris
Sigma-Aldrich
Anti-PAPPA2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution